300760 Shenzhen Mindray Bio-Medical Electronics
- 245.67
- -3.33-1.34%
Shenzhen Mindray Bio-Medical Electronics News
Owning 56% in Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Means That Insiders Are Heavily Invested in the Company's Future
Ping An Securities: The updated policy for medical devices continues to be promoted, and domestic bidding and tendering are expected to significantly improve in the short term.
The update policy for medical field equipment is continuously advancing, and it is expected to gradually land in the second half of 2024. There is hope for significant improvement in domestic bidding and tendering in the short term.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): It is expected that the bid situation in the second half of the year will improve compared with the first half of the year.
In March of this year, the State Council released a notice regarding the "Action Plan for Promoting Large-Scale Equipment Updates and Old-for-New Consumer Goods", which specifically mentioned promoting the iterative upgrading of equipment and information technology facilities in medical and health institutions, encouraging medical institutions that meet the conditions to accelerate the upgrading and transformation of medical equipment, promoting the improvement of ward renovation in medical institutions, and filling in the gaps in ward environment and facilities. Since then, the company has paid close attention to the progress of the project, and various departments such as marketing, R&D, and production supply chain have also prepared related work.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ) will actively participate in the domestic centralized procurement of products such as ultrasonic knives and endoscopic staplers.
Mindray Bio-Medical Electronics (Shenzhen) Co., Ltd. (Stock code: 300760) recently stated during a specific survey that the company has basically completed the product layout of minimally invasive surgery for chest and abdomen with the listing of 4K+ fluorescence and 4K+3D thoracoabdominal endoscopy systems, as well as supporting medical devices and consumables such as electric knives, ultrasonic knives, energy platforms, and laparoscopic anastomotic devices. The company's product competitiveness has reached a leading level in China. Take the intelligent laparoscopic anastomotic device launched this year as an example. Wound anastomosis is a high-risk procedure in the surgical process, so the safety performance of the product is crucial. This is achieved through the product's built-in core technologies.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): Domestic market share of the company's chemiluminescence business this year is expected to surpass that of another imported brand.
Mindray Bio-Medical Electronics (300760.SZ) recently stated during a specific research survey that the chemiluminescence business, an important business that has driven the company's growth for several years in the past and for a considerable period in the future, has always been highly valued by Mindray for its development status. Mindray has continued to invest a high proportion of resources in this business in research and development, marketing, and the supply chain. One major investment by the company was the acquisition of Hybiome. In the nearly three years since the acquisition was completed, the integration of Hybiome has progressed smoothly with the launch of the industry-leading high-sensitivity myocardial protein hs-cTnl last year. This year, the international clinical chemistry and laboratory medicine
Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Could Become A Multi-Bagger
Shenzhen Mindray Bio-Medical Electronics (stock code: 300760.SZ) currently has no business related to brain-computer interface devices.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ) stated on the investor interaction platform on July 25 that the company is currently not involved in the business of brain-computer interface devices.
Nomura Adjusts Shenzhen Mindray Bio-Medical Electronics' Price Target to 425.97 Yuan From 422.45 Yuan, Keeps at Buy
The latest development of Zhu Shaoxing's shareholding has been exposed! He reduced his shareholding in Maotai for two consecutive quarters and increased his holdings in these companies continuously.
Continuously increasing or decreasing shareholdings of these stocks for five consecutive quarters.
An Intrinsic Calculation For Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Suggests It's 27% Undervalued
Jiangsu Leili Motor (300660.SZ): Downstream customers include multiple global medical instrument leading enterprises, such as Shenzhen Mindray Bio-Medical Electronics, IDEXX Laboratories Inc, Siemens, etc.
Jiangsu Leili Motor (300660.SZ) stated on its investor interaction platform on July 3 that the company has accumulated various types of products under categories such as linear actuators and voice coil motors in the medical field. Downstream customers include multiple global medical equipment industry leaders, such as Shenzhen Mindray Bio-medical Electronics, Idexx Laboratories Inc, and Siemens. The company has established a strategic partnership with Shenzhen Mindray Bio-medical Electronics to jointly promote the localization of core components of medical instruments. The company has advantages in excellent product performance, complete series, high global market recognition, outstanding product customization and technical research and development capabilities in the field.
Investor Optimism Abounds Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) But Growth Is Lacking
Could The Market Be Wrong About Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Given Its Attractive Financial Prospects?
Is Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) A Risky Investment?
Mindray Healthcare (300760.SZ) 2023 equity distribution: 15 yuan for every 10 shares. The share registration date is May 27
Mindray Healthcare (300760.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...
Galaxy Securities: The pharmaceutical industry's revenue growth rate is slowing down in 2023, and the worst is expected to pass
The Zhitong Finance App learned that Galaxy Securities released a research report saying that judging from the pace of growth in the pharmaceutical industry, expectations for the whole year are low and moving high. 24Q1 is expected to be the lowest point for the whole year, and a recovery in the pharmaceutical industry's growth rate can be expected from 24Q2. Currently, more emphasis is placed on innovation and device export direction: 1) Pharmaceutical innovation industry upgrading; 2) Colon Pharmaceutical (002422.SZ), etc., a platform-based pharmaceutical company with excellent management; 3) domestic replacement of equipment and overseas exports of Mindray Healthcare (300760.SZ), etc.; 4) Third-party medical testing Jinyu Medicine (603882.SH), etc.; 5) upstream life science,
Illustration丨Capital from North China bucked the trend and added positions to Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare
The net sale of A-shares today was 4,044 billion yuan, the second consecutive day of net sales. Among them, Ping An Bank, Guodian Nanrui, and Zhongji Xuchuang received net sales of 255 million yuan, 242 million yuan, and 204 million yuan respectively; Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare bucked the trend and received net purchases of 395 million yuan, 299 million yuan, and 221 million yuan respectively. According to statistics, the capital from North China has been increasing Kweichow Moutai for 3 consecutive days, for a total of 4.265 billion yuan.
Mindray Healthcare (300760.SZ): The company's products in the field of medical imaging include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS
On May 7, Ge Longhui Medical (300760.SZ) said on the investor interactive platform that the company's products in the field of medical imaging include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS. In the field of ultrasound diagnostic systems, we provide hospitals, clinics, imaging centers, etc. with a full range of ultrasound diagnostic systems covering ultra-high-end to low-end, as well as specialized solutions for gradually segmented applications in different clinical specialties such as radiology, obstetrics and gynecology, intervention, emergency, anesthesia, severe illness, and liver fiber. In the field of digital X-ray imaging, the company provides radiology departments, ICU, and emergency departments including mobile, double column, and suspended models
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Mindray Healthcare (300760.SZ): Model of “Made in China” for medical devices
On the eve of the long holiday, the A-share market performed well. Following a single-day northbound capital inflow that hit a record high since the opening of the Mainland Stock Connect on April 26, the three major A-share indices collectively surged in the intraday market on April 29, and the Shanghai Composite Index once again reached 3,100 points, returning to the annual line. Among them, Mindray Healthcare, the leading medical device company that just released its 2023 report and 2024 quarterly report, also rose sharply with an excellent report card, with an intraday increase of more than 6%. The net capital inflow reached 420 million yuan on the same day, and the net purchase of Land Stock Connect reached 227 million yuan, showing impressive performance. Chart 1: Mindray Healthcare's stock price performance Data source: WIND, GEG
Analysis
Price Target
No Data
